Condition
RETT Syndrome With Proven MECP2 Mutation
Total Trials
5
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 2 (2)
Trial Status
Recruiting2
Enrolling By Invitation1
Not Yet Recruiting1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02110797Not ApplicableCompletedPrimary
Osteoporosis in RETT Syndrome
NCT07493096Recruiting
Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders
NCT07430046Phase 2RecruitingPrimary
Repurposing Mirtazapine in Rett Syndrome
NCT07257978Phase 2Not Yet RecruitingPrimary
Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome
NCT06739434Not ApplicableEnrolling By InvitationPrimary
GCB-002 in Treatment of Patients With Rett Syndrome
Showing all 5 trials